



## PRESS RELEASE

### Information on the total number of voting rights and shares – additional thresholds

**Liège (Belgium), 27 November 2020, 9h00 (CEST) – regulated information** – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Hyloris Pharmaceuticals SA/NV publishes the following information among others following the issuing of a new and additional employee stock option plan (ESOP) on November 27, 2020:

- Share capital: 129.163,16 euro
- Total number of securities carrying voting rights: 25.832.632 (all ordinary shares)
- Total number of voting rights (= denominator): 25.832.632 (all relating to ordinary shares)
- Number of rights to subscribe securities carrying voting rights not yet issued:
  - 400.000 “ESOP Warrants” issued on 27 November 2020, entitling their holders to subscribe for a total number of 400.000 securities carrying voting rights (all ordinary shares)
  - 333.000 “ESOP Warrants” issued on 31 December 2019, entitling their holders to subscribe for a total number of 333.000 securities carrying voting rights (all ordinary shares)
  - 300.000 “Transaction Warrants” issued on 12 May 2017, entitling their holders to subscribe for a total number of 1.200.000 securities carrying voting rights (all ordinary shares)
- In accordance with article 18 of the Law of 2 May 2007 on the disclosure of large shareholdings, the Company has set additional notification thresholds of 3% and 7,5%.

**-Ends-**

**For more information, please contact:**

**Hyloris Pharmaceuticals**

Stijn Van Rompay, CEO

+32 (0)4 346 02 07

[contact@hyloris.com](mailto:contact@hyloris.com)

**Consilium Strategic Communications**

Amber Fennell, Chris Welsh, Lucy Featherstone, Taiana De Ruyck Soares

+44 20 3709 5700

[hyloris@consilium-comms.com](mailto:hyloris@consilium-comms.com)

## **Note to Editors**

### **About Hyloris Pharmaceuticals SA**

Based in Liège, Belgium, Hyloris is an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. Hyloris develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim to address the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system. Hyloris' portfolio spans three areas of focus: IV Cardiovascular, Other Reformulations and Established Market (high-barrier generics). Hyloris currently has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, commercialized through its partner AltaThera, and Maxigesic® IV, a non-opioid analgesic product for the treatment of pain, developed with the Company's partner, AFT Pharmaceuticals. Additionally, Hyloris has 12 product candidates in various stages of development across the Company's wider portfolio. Read more at [www.hyloris.com](http://www.hyloris.com). Hyloris stands for "high yield, lower risk" and relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares.